Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Folic Acid→

Folic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59-30-3
Molecular formula
C19H19N7O6
Molecular weight
441.4 g/mol
Drug class
Vitamin B9folate precursor and one-carbon transfer cofactor
Mechanism of action
Converted to tetrahydrofolate coenzymes that transfer one-carbon units required for purine and thymidylate synthesis, DNA replication, cell division and methionine metabolism.
Indications / reported uses
  • Prevention and treatment of folate deficiency and folate-deficiency megaloblastic anaemia
  • Periconceptional supplementation to reduce risk of neural-tube defects
  • Supplementation in pregnancy or other deficiency-risk settings according to national public-health guidance; folic acid does not treat vitamin B12 deficiency and can mask haematological signs

Sources: NIH Office of Dietary Supplements — Folate fact sheet · CDC — Folic acid and neural-tube-defect prevention · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Folic Acid Environmental Risk Assessment (ERA) (the Folic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.